Andrew J. Armstrong, MD, MSc

Andrew J. Armstrong, MD, MSc, discusses efficacy results from a phase 2 study evaluating a chemoimmunotherapy regimen for patients with neuroendocrine or aggressive-variant metastatic prostate cancer.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.